

Leveraging functional genomics to reveal novel targets for cancer treatment

Horizon Europe

Generated at: October 8, 2026

● PENDING

Code

HORIZON-MISS-2027-02-CANCER-01

Scope

International

Location

Europe

Curator

Marlene Faria

Financial Details

Support type

Non-Refundable

Maximum Funding Rate

100%

Budget

3.2B€

Eligible Project Value

7M€ - 8M€

Dates & Deadlines

Publication Date

Not defined

Opening Date

February 10, 2027

Fase única

September 16, 2027 at 05:00 PM GMT+2

Description

Objectives

This topic aims to advance the understanding of cancer initiation, progression and treatment resistance through the application of functional genomics and multi-omics approaches, contributing directly to the objectives of the EU Cancer Mission. Particular attention is given to paediatric and adolescent cancers, rare cancers, refractory cancers, cancers with limited treatment options, and tumour types with low survival rates. Projects are expected to identify and validate novel therapeutic targets, improve understanding of tumour heterogeneity and resistance mechanisms, and support the development of next-generation genomically informed cancer treatments. Applicants are encouraged to leverage advanced technologies such as single-cell analysis, spatial transcriptomics, liquid biopsies, epigenetic profiling, AI, computational modelling and precision oncology approaches.

Funding

Funding is provided under a Horizon Europe Research and Innovation Action (RIA). The topic has an indicative budget of around €32 million, with the European Commission expecting to fund approximately four projects. The expected EU contribution is between €7 million and €8 million per project, although proposals requesting different amounts may also be considered where appropriately justified. As a Research and Innovation Action, projects are eligible for 100% funding of eligible costs in accordance with Horizon Europe rules.

Eligible Expenses

- Personnel Costs
- Travel costs
- Equipment costs
- Other goods, works and services costs
- Subcontracting
- Indirect Costs

Eligibility

Eligible Sectors

Health & Life Sciences

Application Mode

Consortium / Copromotion

Company Typologies

- Micro
- SME
- Small Mid-Cap
- Mid-Cap
- Large
- Non-business entities of the R&I system (ENESII)
- Private non-profit entities
- Public entities

Action Types

- Research and Innovation Actions
- Clinical Trials
- Digital Health Solutions
- Cross-Border Integration

EU Programme Details

Call ID

HORIZON-MISS-2027-02-CANCER-01

Cluster

Mission

Destination

Cancer

Submission Mode

Single-stage

EU Contribution

Around €7,000,000.00 to €8,000,000.00 per project

Expected Projects

4

Funding Rate Rule

Up to 100% of eligible costs for Research and Innovation Actions (RIA)

Official Links

Official Regulation

<https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-MISS-2027-02-CANCER-01?order=DESC&pageNumber=1&pageSize=50&sortBy=startDate&keywords=HORIZON-MISS-2027-02-CANCER-01&isExactMatch=true&status=31094501,31094502,31094503>

Grantavia page

<https://grantavia.com/en/incentives/leveraging-functional-genomics-to-reveal-novel-targets-for-cancer-treatment>

Schedule a meeting

<https://calendly.com/sandra-cardoso-epsa/reuniao>